The biological age of a person can be determined by measuring DNA methylation levels, a phenomenon known as age acceleration when there is a discrepancy between the predicted age and the biological age. This can be used as a marker of human aging and is possibly associated with cancer risk. As a biological service provider for aging research, CD BioSciences can provide services to investigate the relationship between DNA methylation age acceleration and cancer risks.
Methylation-Based Biological Age and Cancer Risks
DNA methylation levels change with age and have been widely studied as a known biomarker of aging. Several DNA methylation age clocks have appeared and been used. When the age predicted by the methylation clock is greater than the biological age, it is considered to have "age acceleration".
Research suggests a correlation between aging and cancer as well. Predicted ages obtained by DNA methylation analysis are greater than biological age, indicating age acceleration, and these phenomena may also be strongly associated with cancer risk. Analyzing the age acceleration of DNA methylation to discover their association with increased cancer risk or shorter survival, could help to understand the specific relationship between the aging process and cancer development, developing DNA methylation as a tool for predicting cancer risk.
Types of Cancers Associated With Age Acceleration That We Analyze
We provide services for the study of the association between accelerated age based on DNA methylation analysis and the increased risk of various types of cancers, including but not limited to the following:
- Gastric cancers
- Lung cancers
- Kidney cancers
- Breast cancers
- Lymphomas
- Rectal cancers
Technical Routes for Association Analysis of Age Acceleration and Cancers
Our services aim to assess whether DNA methylation age acceleration is associated with cancer risks, primarily through the statistical analysis of age acceleration data obtained from DNA samples at different stages of life.
Our Association Analysis Services for Age Acceleration and Cancers
- DNA methylation age prediction
We perform the DNA methylation analysis of collected samples to determine the DNA methylation level at each CpG locus and to calculate the DNA methylation age of the samples based on the suitable models.
- Age acceleration analysis
We regress the predicted age on the biological age. The age acceleration is calculated according to the residual term of the univariate model, which indicates that the predicted age is greater than the biological age when the result is positive.
- Cancer association analysis
We utilize statistical methods to assess the association between age acceleration and cancer. We perform relevant analyses, including logistic regression, survival analysis, or other appropriate statistical techniques to determine the correlation between age acceleration and cancer occurrence, development, or progression.
CD BioSciences is dedicated to offering customized research services to assist clients in overcoming challenges in DNA methylation age acceleration research, to advance the development of cancer diagnosis and treatment. If you would like more information about our services, please feel free to contact us to discuss how we can advance our aging research journey together.
Reference
- Joo J, et al. DNA methylation-based biological aging and cancer risk and survival: Pooled analysis of seven prospective studies. Cancer Genetics and Epigenetics, 2017.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
